Discover 928 paid clinical trials in Portland, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 928
CGM for the Early Detection and Management of Hyperglycemia in Pregnancy
for
Gestational Diabetes Mellitus in Pregnancy
Location: Portland OR, Saint Louis Park MN, Cleveland OH,
Sponsor: Jaeb Center for Health Research
Sex: Female
Age: 18+
Code: NCT06957028
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
for
Symptomatic Genetic Dilated Cardiomyopathy
Location: Portland OR, San Francisco CA, Stanford CA,
Sponsor: Kardigan, Inc.
Sex: All
Age: 18+
Code: NCT07210723
Phase 2, Phase 3, Recruiting
VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
Location: Portland OR, Los Angeles CA, Nashville TN,
Sponsor: Orca Biosystems, Inc.
Sex: All
Age: 18+
Code: NCT07216443
Phase 2, Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
for
Locally Advanced Cervical Adenocarcinoma,
Location: Portland OR, Clackamas OR, Tualatin OR, Oregon City OR,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07061977
Phase 3, Recruiting
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
for
X-Linked Myotubular Myopathy
Location: Portland OR, Dallas TX, Chicago IL, Toronto, Boston MA
Sponsor: Astellas Gene Therapies
Sex: Male
Age: 0 - 3
Code: NCT07052929
Phase 1, Phase 2, Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer